Raloxifene is as effective as ezetimibe in lowering ApoB and may have cardiovascular benefits.

“I was very much involved with the raloxifene the first CERN that came to the market up as good in April be lowering drug as that am i biz which might have pretended great cardiovascular benefits to the sural oxen which I believe it still has in fact we have some they did a big cardiovascular outcome trial where was no didn't hurt anybody but it didn't reduce events but if you looked at the primary prevention people in their trial it did lower events now post hoc hypothesis generating data but an eight percent a five percent lowering of April B mattered”